Madrigal PharmaceuticalsMDGL
About: Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.
Employees: 376
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
26% more call options, than puts
Call options by funds: $208M | Put options by funds: $165M
1% more repeat investments, than reductions
Existing positions increased: 83 | Existing positions reduced: 82
1% less funds holding
Funds holding: 255 [Q2] → 253 (-2) [Q3]
4% less first-time investments, than exits
New positions opened: 45 | Existing positions closed: 47
4.25% less ownership
Funds ownership: 108.34% [Q2] → 104.09% (-4.25%) [Q3]
26% less capital invested
Capital invested by funds: $6.47B [Q2] → $4.76B (-$1.71B) [Q3]
36% less funds holding in top 10
Funds holding in top 10: 14 [Q2] → 9 (-5) [Q3]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
B. Riley Securities Mayank Mamtani 35% 1-year accuracy 8 / 23 met price target | 24%downside $236 | Neutral Maintained | 5 Nov 2024 |
UBS Eliana Merle 13% 1-year accuracy 2 / 15 met price target | 42%upside $441 | Buy Maintained | 1 Nov 2024 |
Oppenheimer Jay Olson 20% 1-year accuracy 20 / 102 met price target | 13%upside $350 | Outperform Maintained | 23 Oct 2024 |
HC Wainwright & Co. Ed Arce 52% 1-year accuracy 77 / 148 met price target | 25%upside $390 | Buy Reiterated | 22 Oct 2024 |
Financial journalist opinion
